Correspondence 0001193125-24-110274 from Fulcrum Therapeutics, Inc. (FULC) (CIK 0001680581) (FULC)
Fulcrum Therapeutics, Inc. (FULC) (CIK 0001680581)
Date: April 24, 2024 · CIK: 0001680581 · Accession: 0001193125-24-110274
AI Filing Summary & Sentiment
File numbers found in text: 333-277419
Letter
FULCRUM THERAPEUTICS, INC.
26 Landsdowne Street
Cambridge, MA
VIA EDGAR
April 24, 2024
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Fulcrum Therapeutics, Inc.
Acceleration Request for Registration Statement on Form S-3
Filed February 27, 2024
File No. 333-277419
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Fulcrum Therapeutics, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to April 25, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request, please contact Marianne Sarrazin of Goodwin Procter LLP at (415) 733-6134.
Fulcrum Therapeutics, Inc.
/s/ Alan Musso
Alan Musso
cc: Alan Musso, Fulcrum Therapeutics, Inc.
Curt Oltmans, Fulcrum Therapeutics, Inc.
Mitchell Bloom, Goodwin Procter LLP
Marianne Sarrazin, Goodwin Procter LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP FULCRUM THERAPEUTICS, INC. 26 Landsdowne Street Cambridge, MA 02139 VIA EDGAR April 24, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Fulcrum Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 Filed February 27, 2024 File No. 333-277419 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Fulcrum Therapeutics, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to April 25, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable. If you have any questions regarding this request, please contact Marianne Sarrazin of Goodwin Procter LLP at (415) 733-6134. Fulcrum Therapeutics, Inc. /s/ Alan Musso Alan Musso cc: Alan Musso, Fulcrum Therapeutics, Inc. Curt Oltmans, Fulcrum Therapeutics, Inc. Mitchell Bloom, Goodwin Procter LLP Marianne Sarrazin, Goodwin Procter LLP